Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
This article was originally published in The Tan Sheet
Executive Summary
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects
You may also be interested in...
Hamburg/Sharfstein Choice Underscores Public Health, Food Safety
The White House's appointment of two former health commissioners to run FDA sends a strong message that the agency will refocus on public health, particularly food safety
Hamburg/Sharfstein Choice Underscores Public Health, Food Safety
The White House's appointment of two former health commissioners to run FDA sends a strong message that the agency will refocus on public health, particularly food safety
Hamburg/Sharfstein Choice Underscores Public Health, Food Safety
The White House's appointment of two former health commissioners to run FDA sends a strong message that the agency will refocus on public health, particularly food safety